Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LEO 43204 in Scalp Actinic Keratosis
NCT02100813Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- May 2014
- Primary completion
- Mar 2015
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ingenol disoxate in actinic keratosis (AK) (4 arms), sponsored by LEO Pharma. Primary endpoints: Number of Participants Experiencing a Dose-limiting Toxicity and Percent Reduction From Baseline in Actinic Keratosis Lesion Count at Week 8. Started May 2014; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02100813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100813.